Literature DB >> 30592026

A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.

Jacqueline N Poston1,2,3,4, Jonathan R Fromm4,5, Heather A Rasmussen1, Andrei R Shustov2,3,4, Edward N Libby1,2,4, Stephen D Smith1,2,4, Ted Gooley2, Ajay K Gopal1,2,4.   

Abstract

Entities:  

Keywords:  CD30; Hodgkin lymphoma; anaplastic large cell lymphoma; brentuximab vedotin

Mesh：

Substances：

Year:  2018        PMID： 30592026      PMCID： PMC6589112          DOI： 10.1111/bjh.15742

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Robert Chen; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Joseph M Connors; Andreas Engert; Emily K Larsen; Dirk Huebner; Abraham Fong; Anas Younes
Journal:  Blood       Date:  2016-07-18       Impact factor: 22.113

2.  Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure.

Authors:  Nitya Nathwani; Amrita Y Krishnan; Qin Huang; Young Kim; Chatchada Karanes; Eileen P Smith; Stephen J Forman; Eric Sievers; Sandra H Thomas; Robert W Chen
Journal:  Leuk Lymphoma       Date:  2012-04-18

3.  Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Authors:  Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.

Authors:  Michelle A Fanale; Andres Forero-Torres; Joseph D Rosenblatt; Ranjana H Advani; Anna R Franklin; Dana A Kennedy; Tae H Han; Eric L Sievers; Nancy L Bartlett
Journal:  Clin Cancer Res       Date:  2011-11-11       Impact factor: 12.531

6.  Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting.

Authors:  Jonathan R Fromm; Anju Thomas; Brent L Wood
Journal:  Am J Pathol       Date:  2016-12-18       Impact factor: 4.307

7.  Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Keenan Fenton; Dirk Huebner; Juan M Pinelli; Dana A Kennedy; Andrei Shustov
Journal:  Blood       Date:  2017-10-03       Impact factor: 22.113

8.  Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

Authors:  Alex F Herrera; Alison J Moskowitz; Nancy L Bartlett; Julie M Vose; Radhakrishnan Ramchandren; Tatyana A Feldman; Ann S LaCasce; Stephen M Ansell; Craig H Moskowitz; Keenan Fenton; Carol Anne Ogden; David Taft; Qu Zhang; Kazunobu Kato; Mary Campbell; Ranjana H Advani
Journal:  Blood       Date:  2017-12-11       Impact factor: 25.476

9.  Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

Authors:  Nancy L Bartlett; Robert Chen; Michelle A Fanale; Pauline Brice; Ajay Gopal; Scott E Smith; Ranjana Advani; Jeffrey V Matous; Radhakrishnan Ramchandren; Joseph D Rosenblatt; Dirk Huebner; Pamela Levine; Laurie Grove; Andres Forero-Torres
Journal:  J Hematol Oncol       Date:  2014-03-19       Impact factor: 17.388
  9 in total
  1 in total

1.  Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.

Authors:  Robert Chen; Alex F Herrera; Jessie Hou; Lu Chen; Jun Wu; Yuming Guo; Timothy W Synold; Vu N Ngo; Sandrine Puverel; Matthew Mei; Leslie Popplewell; Shuhua Yi; Joo Y Song; Shu Tao; Xiwei Wu; Wing C Chan; Stephen J Forman; Larry W Kwak; Steven T Rosen; Edward M Newman
Journal:  Clin Cancer Res       Date:  2019-12-06       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.